The DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index; 28 of the 31 sources its claims cite were checked for support.
Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease
Open accessAbstract
Blood biomarkers indicating elevated amyloid-β (Aβ) pathology in preclinical Alzheimer’s disease are needed to facilitate the initial screening process of participants in disease-modifying trials. Previous biofluid data suggest that phosphorylated tau231 (p-tau231) could indicate incipient Aβ pathology, but a comprehensive comparison with other putative blood biomarkers is lacking. In the ALFA+ cohort, all tested plasma biomarkers (p-tau181, p-tau217, p-tau231, GFAP, NfL and Aβ42/40) were significantly changed in preclinical Alzheimer’s disease. However, plasma p-tau231 reached abnormal levels with the lowest Aβ burden. Plasma p-tau231 and p-tau217 had the strongest association with Aβ positron emission tomography (PET) retention in early accumulating regions and associated with longitudinal increases in Aβ PET uptake in individuals without overt Aβ pathology at baseline. In summary, plasma p-tau231 and p-tau217 better capture the earliest cerebral Aβ changes, before overt Aβ plaque pathology is present, and are promising blood biomarkers to enrich a preclinical population for Alzheimer’s disease clinical trials.
Overview
CoChat Summary
TL;DR
In the ALFA+ cohort, plasma p-tau231 and p-tau217 best captured the earliest amyloid-β changes in preclinical Alzheimer’s disease, with p-tau231 becoming abnormal at the lowest Aβ PET burden. These biomarkers may help enrich preclinical trial populations, though platform and cohort limitations remain.
Key findings
- All tested plasma biomarkers (p-tau181, p-tau217, p-tau231, GFAP, NfL, Aβ42/40) were significantly changed in preclinical AD, but plasma p-tau231 reached abnormal levels earliest, at 26.4 Centiloids, followed by p-tau217 at 35.4 Centiloids and GFAP at 65.5 Centiloids; p-tau181, NfL and Aβ42/40 did not reach the two z-score abnormality threshold.
- Plasma p-tau231 and p-tau217 had the strongest associations with Aβ PET retention in early-accumulating regions, including orbitofrontal areas, anterior and posterior cingulate gyri, insula and precuneus.
- In participants without established Aβ pathology at baseline (Aβ PET <30 Centiloids), only plasma p-tau231 and p-tau217 were significantly associated with longitudinal Aβ PET Centiloid increases at follow-up (P = 0.041 for both).
- For discriminating Aβ status by CSF Aβ42/40, the highest AUCs were plasma Aβ42/40 (AUC = 0.750, 95% CI = 0.702–0.798) and p-tau231 (AUC = 0.740, 95% CI = 0.688–0.793); combined with age, sex and APOE ε4, p-tau231 reached AUC = 0.810 (95% CI = 0.766–0.854), Aβ42/40 AUC = 0.798 (95% CI = 0.754–0.843) and p-tau217 AUC = 0.797 (95% CI = 0.751–0.842).
Methods
- Design and sample: ALFA+ cohort study of 397 cognitively unimpaired middle-aged individuals (61.1 ± 4.67 years), including 135 (34.0%) Aβ-positive by CSF Aβ42/40; 339 had baseline Aβ PET, and subsets had 3-year longitudinal cognitive (n = 214) and Aβ PET (n = 145) data.
- Biomarkers and imaging: plasma p-tau181, p-tau217, p-tau231, GFAP, NfL and Aβ42/40; CSF Aβ42/40 and M-p-tau181; [18F]flutemetamol Aβ PET quantified in Centiloids with early (≥12) and later (≥30) cut-offs.
- Analysis: ANCOVA and Cohen’s d for group differences; robust local weighted regression for biomarker trajectories; voxel-wise linear regression for Aβ PET associations; ROC/AUC with DeLong’s test; linear regression for longitudinal cognitive and Aβ PET change.
Limitations
- Stated in the paper: different platforms were used to measure plasma biomarkers, and the contribution of assay platform to diagnostic accuracy remains unclear.
- Stated in the paper: ALFA+ includes participants with higher AD risk by design (high APOE ε4 carriership and Aβ positivity) and does not represent normal aging in the general population.
- Evident from the text: the main biomarker comparisons are cross-sectional, and longitudinal analyses rely on smaller subsets (n = 214 for cognition; n = 145 for Aβ PET), with no external independent validation cohort reported.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
13 Valid · 0 Not valid · 1 Not checked · 37 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our choice of 30 Centiloids as a later cut-off was based on our previous findings that it has the best agreement with the CSF t-tau/Aβ42 ratio in pooled data of ALFA+ and AD neuroimaging (ADNI) cohort biomarkers18.”
§ Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease > Methods > Participant characteristics
What the sources say
- Supportedcites [18] Salvadó, G. et al. Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. Alzheimers Res. Ther. 11, 27 (2019). source
The Results section (‘CSF tau/Aβ42 ratios and tau’; page not provided) reports that, with ALFA+ and ADNI data merged, the optimal cut-off for the CSF tTau/Aβ42 ratio was 29.7 Centiloids by Youden’s index and 30.1 by overall percentage agreement. Both support the citing sentence’s rounded value of 30 Centiloids. (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“CSF p-tau231 showed the earliest change in association with Aβ pathology in the AD brain9,14.”
§ Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease > Main
What the sources say
- Supportedcites [9] Suárez-Calvet, M. et al. Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected. EMBO Mol. Med. 12, e12921 (2020). source
In Results (Modelling of p-tau biomarker changes across the preclinical Alzheimer’s continuum; page unavailable), CSF Mid-p-tau231 was the first measured p-tau biomarker to cross the study’s 2-z-score abnormality threshold as Aβ pathology increased. The analysis using Aβ PET showed the same ordering. This supports the claim as a comparison of modelled biomarker changes, rather than a longitudinal observation. (LLM, conf=0.88)
- Supportedcites [14] Ashton, N. J. et al. Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer’s disease. eBioMedicine 76, 103836 (2022). source
The Findings state that CSF p-tau231 attained abnormal levels first and was sensitive to the earliest regional Aβ changes before global PET positivity. The Discussion specifies that this was among the p-tau biomarkers tested. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In some instances1, the performance of plasma p-tau biomarkers is comparable or only marginally inferior to established cerebrospinal fluid (CSF) or PET examinations of Aβ and tau pathologies, but with the advantage of greater availability and tolerability for both clinicians and patients.”
§ Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease > Main
What the sources say
- Supportedcites [1] Palmqvist, S. et al. Discriminative accuracy of plasma Phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324, 772 (2020). source
The Discussion reports that plasma P-tau217 and tau-PET did not differ significantly in distinguishing Alzheimer dementia from other neurodegenerative diseases. The Accuracy section also reports performance comparable to CSF P-tau217 for identifying abnormal tau-PET scans, while CSF measures performed better for Aβ-PET status. These findings support the qualified phrase “in some instances.” (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In particular, the highest AUCs were for risk factors combined with plasma p-tau231 (AUC = 0.810 (95% CI = 0.766–0.854)), plasma Aβ42/40 (AUC = 0.798 (95% CI = 0.754–0.843)) and plasma p-tau217 (AUC = 0.797 (95% CI = 0.751–0.842)) (Table 1 and Extended Data Fig. 3).”
§ Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease > Main
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In contrast, the other biomarkers had weaker and less widespread associations across the brain with, in particular, less involvement of the insula (Fig. 1e).”
§ Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease > Main
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
17 more claims
Create a free account to see all 51 claims and every source verdict.
- Probably not a substantial claim. 14
- It may state two separate claims as one. 20
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A combination of multiple blood-based biomarkers and demographic information, like age and sex, may allow for determining individualised risk of developing AD dementia and this has been done in an MCI population.(455)”
From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [455]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Plasma p-tau181, p-tau217, and p-tau231 have a good or better accuracy than amyloid CSF Abeta and tau and PET measures of tau and amyloid pathology in discriminating people with amyloid pathology who may have clinical symptoms.(452-454)”
From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [454]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Abnormality for plasma biomarkers was determined in a standardized manner across all cohorts using z-scores created based on the means and s.d. of cognitively unimpaired individuals without elevated amyloid-β pathology, as previously done in several studies8,62,63.”
From Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability (2024) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Plasma levels of p-tau are strongly associated with PET and CSF biomarkers of AD pathology19–25, neuropathological changes associated with AD20,23,26,27 and the subsequent development of AD dementia20,23,28.”
From Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests (2024) · cites this paper as [22]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Abnormality for plasma biomarkers was determined in a standardized manner across all cohorts using z-scores created based on the means and s.d. of cognitively unimpaired individuals without elevated amyloid-β pathology, as previously done in several studies8,62,63.”
From Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability (2024) · cites this paper as [63]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationPalmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603
Self-citationThe Centiloid Project: standardizing quantitative amyloid plaque estimation by PET
Klunk, W. E., Koeppe, R. A., Price, J. C., Benzinger, T. L., Devous, M. D., Jagust, W. J., Johnson, K. A., Mathis, C. A., Minhas, D., Pontecorvo, M. J., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.07.003 · Cited by 1,348
Karikari, T. K., Pascoal, T. A., Ashton, N. J., Janelidze, S., Benedet, A. L., Rodriguez, J. L., Chamoun, M., Savard, M., Kang, M. S., Therriault, J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30071-5 · Cited by 1,316
Self-citationCSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
Self-citationJanelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T. G., Serrano, G. E., Chai, X., Proctor, N. K., Eichenlaub, U., Zetterberg, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0755-1 · Cited by 1,247
Self-citationThe Preclinical Alzheimer Cognitive Composite: Measuring Amyloid-Related Decline
Donohue, M. C., Sperling, R. A., Salmon, D. P., Rentz, D. M., Raman, R., Thomas, R. G., Weiner, M., & Aisen, P. S. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.803 · Cited by 860
Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology.
Ashton, N. J., Pascoal, T. A., Karikari, T. K., Benedet, A. L., Lantero-Rodriguez, J., Brinkmalm, G., Snellman, A., Schöll, M., Troakes, C., Hye, A., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02275-6 · Cited by 719
Self-citationBenedet, A. L., Milà-Alomà, M., Vrillon, A., Ashton, N. J., Pascoal, T. A., Lussier, F., Karikari, T. K., Hourregue, C., Cognat, E., Dumurgier, J., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.3671 · Cited by 638
Self-citation
Cited by
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., Ames, D., Banerjee, S., Burns, A., Brayne, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01296-0 · Cited by 3,860
Blood biomarkers for Alzheimer’s disease in clinical practice and trials
Hansson, O., Blennow, K., Zetterberg, H., & Dage, J. (2023) · Nature Aging · doi:10.1038/s43587-023-00403-3 · Cited by 522
Self-citationOssenkoppele, R., Pichet Binette, A., Groot, C., Smith, R., Strandberg, O., Palmqvist, S., Stomrud, E., Tideman, P., Ohlsson, T., Jögi, J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02049-x · Cited by 496
Barthélemy, N. R., Salvadó, G., Schindler, S. E., He, Y., Janelidze, S., Collij, L. E., Saef, B., Henson, R. L., Chen, C. D., Gordon, B. A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02869-z · Cited by 448
“Detection of Aβ positivity using mass spectrometry %p-tau217 in cognitively normal cohorts appears better than what has been reported when using plasma p-tau217 immunoas-says, although this must be confirmed in head-to-head studies 22,23,48–50 .”
MethodSelf-citationAshton, N. J., Janelidze, S., Mattsson-Carlgren, N., Binette, A. P., Strandberg, O., Brum, W. S., Karikari, T. K., González-Ortiz, F., Di Molfetta, G., Meda, F. J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02074-w · Cited by 436
Self-citation
Metadata
- Authors
- Milà-Alomà, M., Ashton, N. J., Shekari, M., Salvadó, G., Ortiz-Romero, P., Montoliu-Gaya, L., Benedet, A. L., Karikari, T. K., Lantero-Rodriguez, J., Vanmechelen, E., Day, T. A., González-Escalante, A., Sánchez-Benavides, G., Minguillon, C., Fauria, K., Molinuevo, J. L., Dage, J. L., Zetterberg, H., Gispert, J. D., Suárez-Calvet, M., & Blennow, K.
- Affiliations
- King's College London (GB)
- Universitat Pompeu Fabra (ES)
- Instituto de Salud Carlos III (ES)
- University of Pittsburgh (US)
- ADx NeuroSciences (BE)
- Eli Lilly (United States) (US)
- Sahlgrenska University Hospital (SE)
- Corresponding author
- Blennow, Kaj
- ORCID
- Venue
- Nature Medicine
- Published
- 2022-08-11
- Volume
- 28
- Issue
- 9
- Pages
- 1797-1801
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC9499867
- OpenAlex
- W4292865371
- Cited by
- 353
- References
- 33
- Citations by year
- 2026: 47 · 2025: 105 · 2024: 122 · 2023: 69 · 2022: 10
- FWCI
- 47.32
- Type
- journal article
- Language
- en
- Update notices
- correction (2022-09-13)
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- IUScholarWorks (Indiana University) (submittedVersion, cc-by)
- Research Portal (King's College London) (submittedVersion, cc-by)
- UCL Discovery (University College London) (submittedVersion)
- Repositori digital de la UPF (Universitat Pompeu Fabra) (submittedVersion, cc-by)
- Funders
- Alzheimer's Association (ADSF-21-831377-C, ZEN-21-848495, 21-831376 -C, ADSF‐21‐831376‐C, ADSF-21-831376-C, ADSF-21-831381-C and ADSF-21-831377-C, #ADSF-21-831381-C, 100010434, 2021 Zenith Award, JPND2019-466-236, -21-831381-C, TriBEKa-17-519007, -21- 831377-C)
- Alzheimer's Drug Discovery Foundation (2016862, FO2017-0243, 201809, ADSF-21-831381-C, 2017-00915, #ALFGBG-715986, ZEN-21-848495, 201809–2016862, ADSF-21-831377-C, 860197, JPND2019-466-236, 201809-2016615, #ADSF-21-831376-C, #RDAPB‐201809‐2016615, AF-742881)
- Eli Lilly and Company
- Familjen Erling-Perssons Stiftelse (#FO2017-0243, FO2019-0228, ALZ2022-0006, 860197)
- Stiftelsen för Gamla Tjänarinnor (860197, FO2019‐0228, 2017-00915)
- Agentschap Innoveren en Ondernemen (140105)
- EU Joint Programme – Neurodegenerative Disease Research (JPND2019-466-236)
- European Federation of Pharmaceutical Industries and Associations (115952, RYC-2013-13054)
- Ministerio de Ciencia, Innovación y Universidades (RTI2018‑102261, 100010434, RYC-2013-13054, RTI2018)
- University College London
- European Commission (100010434, 847648, 948677, 115952, HORIZON2020, ZEN-21-848495, JPND2019‐466‐236, 860197, ID 100010434)
- ZonMw (733051102)
- Fonds National de la Recherche Luxembourg
- Bundesministerium für Bildung und Forschung
- Ministerio de Economía y Competitividad (JPND2019-466-236, RYC‐2013‐13054, ZEN-21-848495, 100010434)
- Hjärnfonden (ALZ2022-0006), FO2017‑0243, FO2017, ALFGBG-715986, FO2019‐0228, #ALFGBG-965240, JPND2019-466-236)
- Vetenskapsrådet (ALFGBG-965240, ALZ2022-0006, 860197, 2017-00915, (#ALFGBG-715986, PI19/00155, 948677, ZEN-21-848495, 681712, 2018-, JPND2019-466-236, FO2017-0243, 2018-02532)
- Vlaamse regering
- UK Dementia Research Institute (#2017-00915, ZEN-21-848495, ALFGBG-715986, RDAPB-201809-2016615, #ALZ2022-0006, AF-968270, FO2017-0243, -965240, -968270, -939721, ALFGBG-965240, -201809-2016615, AF-930351, -715986, -930351, AF-939721)
- Olav Thon Stiftelsen (#FO2019-0228)
- National Institutes of Health (ID 100010434, ZEN-21- 848495, 100010434, 2018-02532)
- Instituto de Salud Carlos III (ID 100010434, 100010434, PI19/00155)
- National Research, Development and Innovation Office
- National Institute on Aging (R01AG068398)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- preclinical Alzheimer's disease, amyloid-beta pathology, phosphorylated tau217, plasma biomarkers, blood biomarkers, amyloid PET, disease-modifying trials, trial participant selection, glial fibrillary acidic protein, neurofilament light chain
- MeSH terms
- Alzheimer Disease, Humans, Biomarkers, Amyloid beta-Peptides, tau Proteins, Positron-Emission Tomography, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-27, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-27 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease. https://app.cochat.ai/papers/10.1038/s41591-022-01925-w
- The paper
- Milà-Alomà, M., Ashton, N. J., Shekari, M., Salvadó, G., Ortiz-Romero, P., Montoliu-Gaya, L., Benedet, A. L., Karikari, T. K., Lantero-Rodriguez, J., Vanmechelen, E., Day, T. A., González-Escalante, A., Sánchez-Benavides, G., Minguillon, C., Fauria, K., Molinuevo, J. L., Dage, J. L., Zetterberg, H., Gispert, J. D., . . . Blennow, K. (2022). Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease. Nature Medicine. https://doi.org/10.1038/s41591-022-01925-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.